British pharmaceutical giant Astrazeneca today withdrew its Covid-19 vaccine Vaxzevria from the market, for commercial reasons, one of the first to be marketed during the pandemic.
“Given that multiple vaccines against Covid-19 have been developed, there is a surplus of updated vaccines” given the different variants of the virus, “which has resulted in a decrease in demand”, explained the pharmaceutical company, in a statement.
The announcement that the vaccine would no longer be sold from today had been made at the beginning of the week by the pharmaceutical company.
At the end of April, the European Medicines Agency (EMA) recommended updating Covid-19 vaccines for the 2024/2025 vaccination campaign, to protect against the new variant of the SARS-CoV-2 virus. , JN.1.
“JN.1 differs from the XBB family targeted by previous updated vaccines and has now surpassed the XBB variants to become the most circulating variant around the world”, he highlights.
Companies currently developing new Covid-19 vaccines that do not target JN.1 were also encouraged to contact the EMA to discuss strategies for changing the composition of their vaccines.
Tags: Astrazeneca withdraws Covid19 vaccine market
